Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.77 and traded as low as $9.64. Astellas Pharma shares last traded at $9.71, with a volume of 89,294 shares.
Astellas Pharma Stock Up 2.1 %
The company has a market capitalization of $17.92 billion, a PE ratio of -45.00 and a beta of 0.34. The stock's fifty day moving average is $9.62 and its two-hundred day moving average is $10.73. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, analysts predict that Astellas Pharma Inc. will post 0.42 EPS for the current year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Stories
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
